Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (Q38415577)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 February 2015

Language	Label	Description	Also known as
English	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.	scientific article published on 26 February 2015

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. (English)

1 reference

Europe PubMed Central

2 September 2017

15

object named as

Julià Blanco

0 references

object named as

Beatriz Mothe

1

0 references

Maria Carmen Puertas

object named as

María C Puertas

7

0 references

object named as

Jorge Carrillo

8

0 references

Javier Martinez-Picado

object named as

Javier Martinez-Picado

17

0 references

Christian Brander

object named as

Christian Brander

29

0 references

object named as

Felipe García

30

0 references

object named as

Agathe León

10

0 references

object named as

José Alcamí

16

0 references

Bonaventura Clotet Sala

14

object named as

Bonaventura Clotet

1 reference

Europe PubMed Central

2 September 2017

Mª Ángeles Muñoz-Fernández

6

object named as

María Ángeles Muñoz-Fernández

1 reference

Europe PubMed Central

2 September 2017

José Luis Jiménez

5

object named as

José Luis Jiménez

1 reference

Europe PubMed Central

2 September 2017

Mariano Esteban

27

object named as

Mariano Esteban

1 reference

Europe PubMed Central

2 September 2017

Beatriz Perdiguero

25

object named as

Beatriz Perdiguero

1 reference

Europe PubMed Central

2 September 2017

Juan García-Arriaza

26

object named as

Juan García-Arriaza

1 reference

Europe PubMed Central

2 September 2017

Carmen E Gómez

24

object named as

Carmen E Gómez

1 reference

Europe PubMed Central

2 September 2017

Juan Carlos López Bernaldo de Quirós

28

object named as

Juan Carlos López Bernaldo de Quirós

1 reference

Europe PubMed Central

2 September 2017

11

object named as

Judit Pich

1 reference

Europe PubMed Central

2 September 2017

Joan Albert Arnaiz

12

object named as

Joan Albert Arnaiz

1 reference

Europe PubMed Central

2 September 2017

Josep Maria Gatell

13

object named as

Jose M Gatell

1 reference

Europe PubMed Central

2 September 2017

Norma I Rallón

23

object named as

Norma Rallón

1 reference

Europe PubMed Central

2 September 2017

Montserrat Plana

3

object named as

Montserrat Plana

1 reference

Europe PubMed Central

2 September 2017

author name string

Nuria Climent

2

1 reference

Europe PubMed Central

2 September 2017

Miriam Rosàs

4

1 reference

Europe PubMed Central

2 September 2017

Nuria Gonzalez

9

1 reference

Europe PubMed Central

2 September 2017

Carmen Alvarez-Fernández

18

1 reference

Europe PubMed Central

2 September 2017

Sonsoles Sánchez-Palomino

19

1 reference

Europe PubMed Central

2 September 2017

Alberto C Guardo

20

1 reference

Europe PubMed Central

2 September 2017

José Peña

21

1 reference

Europe PubMed Central

2 September 2017

José M Benito

22

1 reference

Europe PubMed Central

2 September 2017

RISVAC-03 Study Group

31

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

26 February 2015

1 reference

Europe PubMed Central

2 September 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

2 September 2017

70

1 reference

Europe PubMed Central

2 September 2017

1833-1842

1 reference

Europe PubMed Central

2 September 2017

6

1 reference

Europe PubMed Central

2 September 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

A therapeutic dendritic cell-based vaccine for HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Definition of the viral targets of protective HIV-1-specific T cell responses

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Clinical applications of attenuated MVA poxvirus strain.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Therapeutic vaccines against HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Long-term Clinical Follow-up, without Antiretroviral Therapy, of Patients with Chronic HIV-1 Infection with Good Virological Response to Structured Treatment Interruption

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Therapeutic Immunization with Dendritic Cells Loaded with Heat‐Inactivated Autologous HIV‐1 in Patients with Chronic HIV‐1 Infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Biphasic decline of CD4 cell count during scheduled treatment interruptions

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV046

21 January 2018

Identifiers

10.1093/JAC/DKV046

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38415577&oldid=2019631413"